211 related articles for article (PubMed ID: 16709035)
1. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
Chang SM; Butowski NA; Sneed PK; Garner IV
Neurosurg Focus; 2006 Apr; 20(4):E4. PubMed ID: 16709035
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
3. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
4. Designer therapies for glioblastoma multiforme.
Sathornsumetee S; Rich JN
Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
[TBL] [Abstract][Full Text] [Related]
5. Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay.
Glantz M; Kesari S; Recht L; Fleischhack G; Van Horn A
Semin Oncol; 2009 Aug; 36(4 Suppl 2):S17-24. PubMed ID: 19660679
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
8. Evolving strategies: future treatment of glioblastoma.
Chamberlain M
Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma multiforme: a review of where we have been and where we are going.
Adamson C; Kanu OO; Mehta AI; Di C; Lin N; Mattox AK; Bigner DD
Expert Opin Investig Drugs; 2009 Aug; 18(8):1061-83. PubMed ID: 19555299
[TBL] [Abstract][Full Text] [Related]
10. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy.
Mandl ES; Dirven CM; Buis DR; Postma TJ; Vandertop WP
Surg Neurol; 2008 May; 69(5):506-9; discussion 509. PubMed ID: 18262245
[TBL] [Abstract][Full Text] [Related]
11. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
Jagannathan J; Prevedello DM; Dumont AS; Laws ER
Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of recurrent high-grade astrocytoma.
Butowski NA; Sneed PK; Chang SM
J Clin Oncol; 2006 Mar; 24(8):1273-80. PubMed ID: 16525182
[TBL] [Abstract][Full Text] [Related]
13. Recurrent glioblastoma multiforme: a review of natural history and management options.
Hou LC; Veeravagu A; Hsu AR; Tse VC
Neurosurg Focus; 2006 Apr; 20(4):E5. PubMed ID: 16709036
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma multiforme: evidence-based approach to therapy.
Nicholas MK
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S23-7. PubMed ID: 18076314
[TBL] [Abstract][Full Text] [Related]
15. Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network.
Weber DC; Miller RC; Villà S; Hanssens P; Baumert BG; Castadot P; Varlet P; Abacioglu U; Igdem S; Szutowicz E; Nishioka H; Hofer S; Rutz HP; Ozsahin M; Taghian A; Mirimanoff RO
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):179-86. PubMed ID: 16814953
[TBL] [Abstract][Full Text] [Related]
16. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.
Glas M; Hundsberger T; Stuplich M; Wiewrodt D; Kurzwelly D; Nguyen-Huu B; Rasch K; Herrlinger U
Oncology; 2009; 76(3):184-9. PubMed ID: 19218824
[TBL] [Abstract][Full Text] [Related]
17. Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.
Ferroli P; Broggi M; Franzini A; Maccagnano E; Lamperti M; Boiardi A; Broggi G
Neurosurgery; 2006 Aug; 59(2):E433-4; discussion E433-4. PubMed ID: 16883158
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
19. Use of nanoparticles for drug delivery in glioblastoma multiforme.
Jain KK
Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
[TBL] [Abstract][Full Text] [Related]
20. Surgical management of high-grade gliomas.
Hsieh JC; Lesniak MS
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S33-9. PubMed ID: 16274269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
